We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Liminal Biosciences Inc (LMNL) NPV

Sell:$0.47 Buy:$0.55 Change: $0.0168 (3.28%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.0168 (3.28%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.0168 (3.28%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Liminal BioSciences Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on discovery and development of small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases. Its lead small molecule product candidate, fezagepras (PBI-4050) has completed the clinical phase of the Phase I multi-ascending dose, (MAD), clinical trial and the Company is in the process of evaluating the pharmacokinetic (PK) data set from the phase I MAD clinical trial. The Company is also developing a selective GPR84 antagonist candidate and an oral, selective OXER1 antagonist candidate. The GPR84 and OXER1 antagonist programs are in the preclinical stage. GPR84 is an inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase during periods of inflammatory stress. OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE).

Contact details

231 Dundas Street East
K8N 1E2
+1 (450) 7810115

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$13.97 million
Shares in issue:
31.04 million
US dollar

Key personnel

  • Patrick Sartore
  • Bruce Pritchard
    Chief Executive Officer
  • N. Nicole Rusaw
    Interim Chief Financial Officer
  • Marie Iskra
    General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.